வர்ஜீனியா சிறுநீரகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வர்ஜீனியா சிறுநீரகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வர்ஜீனியா சிறுநீரகம் Today - Breaking & Trending Today

The NCAA Takes Exception To "Vasectomy Mayhem" Trademark | Shenandoah Country Q102


By Lori
The trademarked phrase Vasectomy Mayhem is causing a stir with the NCAA.
The governing body of college sports filed a trademark complaint last month against Virginia Urology, claiming it bears a close resemblance to its famous March Madness basketball tournament. The NCAA argues it will result in confusion, mistake or deception.
The Patent and Trademark Office OK d Vasectomy Mayhem back in September. The NCAA has rights not only for March Madness, but names close to it such as March Mayhem, Munch Madness, and Midnight Madness.
The doctor’s office has taken liberties, including using two basketballs in its ad. The commercial notes Call now to align your couch time with optimal tube time for the best games.” ....

United States , Trademark Office Okd Vasectomy Mayhem , Virginia Urology , March Madness , Trademark Office , March Mayhem , Munch Madness , Vasectomy Mayhem , ஒன்றுபட்டது மாநிலங்களில் , முத்திரை அலுவலகம் ஓக்ட் வாஸெக்டோமி சகதியில் , வர்ஜீனியா சிறுநீரகம் , அணிவகுப்பு பைத்தியம் , முத்திரை அலுவலகம் , அணிவகுப்பு சகதியில் , மன்ச் பைத்தியம் , வாஸெக்டோமி சகதியில் ,

Theralase Technologies Inc.: Theralase Launches First Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study


Theralase Technologies Inc.: Theralase Launches First Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
TSXV:TLT)(
OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (
PDC ) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Virginia Urology (
VU ) has received site Institutional Review Board (
IRB ) approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer (
NMIBC ) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(

Study II ).
Theralase has central IRB approval to launch a number of US clinical sites, subject to local site IRB approval. VU is the first site to receive both central and local site IRB approval. There are 5 additional US clinical study sites that have received central IRB approval and are exp ....

United States , Kristina Hachey , Calmette Guerin , Vu Research Department , Technologies Inc , Theralase Or Company , Venture Exchange , Regulation Services Provider , Theralase Technologies Inc , Photo Dynamic Compounds , Virginia Urology , Institutional Review Board , Muscle Invasive Bladder Cancer , Clinical Study , Bacillus Calmette Guerin , Unresponsive Carcinoma In Situ , Greater Richmond , Urologic Oncologist , Photodynamic Therapy , Shirazi Phd , Chief Executive Officer , Therapeutic Dose , Complete Response , Adverse Events , Looking Statement , More Information ,